Novartis AG Common Stock (NVS)

Total Current Liabilities

$31.75B

Quarterly · Period ending: · USD

NVS logo

NVS Total Current Liabilities

Latest reported$31.75B
NVS Quarterly Current Liabilities ($8.94B → $31.75B)
High-resolution chart · PNG

NVS total current liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock Total Current Liabilities — Quarterly (USD)
Period endingTotal Current Liabilities (USD)
31,748,127,000
31,374,000,000
27,278,047,000
32,000,000,000
31,714,000,000
31,619,000,000
28,692,000,000
28,132,000,000
27,612,000,000
29,288,000,000
26,389,948,038
48,393,000,000
31,909,000,000
30,549,000,000
28,656,069,347
28,160,000,000
27,646,000,000
29,807,000,000
30,208,000,000
29,880,000,000
29,633,000,000
30,160,000,000
33,059,000,000
31,838,000,000
29,382,000,000
31,294,000,000
28,263,877,842
28,220,000,000
30,111,000,000
56,127,000,000
29,607,000,000
28,327,000,000
27,943,000,000
28,223,000,000
23,403,000,000
25,379,000,000
26,146,000,000
26,330,000,000
22,209,000,000
24,604,000,000
26,271,000,000
27,817,000,000
23,708,000,000
28,158,000,000
29,389,000,000
29,053,000,000
26,973,000,000
26,616,000,000
27,556,000,000
24,760,000,000
26,368,000,000
25,812,000,000
24,388,000,000
26,369,000,000
24,051,000,000
21,859,000,000
24,920,000,000
27,356,000,000
23,148,000,000
25,830,000,000
29,536,000,000
32,216,000,000
24,658,000,000
27,657,000,000
17,829,000,000
17,432,000,000
19,470,000,000
17,902,000,000
15,358,000,000
14,990,000,000
16,504,000,000
19,954,000,000
19,683,000,000
17,056,000,000
16,641,000,000
17,501,000,000
15,980,000,000
17,549,000,000
16,234,000,000
16,315,000,000
16,757,000,000
15,590,000,000
15,328,000,000
12,457,000,000
12,643,000,000
11,322,000,000
11,078,000,000
8,984,000,000
8,990,000,000
9,421,000,000
9,320,000,000
8,345,000,000
9,820,000,000
9,541,000,000
8,294,000,000
8,281,000,000
8,115,000,000
8,587,000,000
8,131,000,000
7,097,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.